Evidence map›Paper›PMID 36538188›Full record

ArticleInternal and emergency medicine2023

Serological response to COVID-19 pneumonia and increasing severity over 18 months in a prospective cohort of hospitalized patients.

Gemma Grau Gómez, Xavier Martínez Lacasa, Roser Costa, Bienvenido Barreiro, Miguel Leal, Emma Padilla, Pepa Pérez, Marc Garreta, Judith Vidal, Angeles Jaen and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Internal and emergency medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Gemma Grau GómezInternal Medicine Department, Fundació Mútua Terrassa, Plaça del Doctor Robert, 5, 08221, Terrassa, Barcelona, Spain. gemma.grau27@gmail.com.ORCID http://orcid.org/0000-0003-0587-1502
Xavier Martínez LacasaInternal Medicine Department, Fundació Mútua Terrassa, Plaça del Doctor Robert, 5, 08221, Terrassa, Barcelona, Spain.
Roser CostaPneumology Department, Fundació Mútua Terrassa, Terrassa, Barcelona, Spain.
Bienvenido BarreiroPneumology Department, Fundació Mútua Terrassa, Terrassa, Barcelona, Spain.
Miguel LealPneumology Department, Fundació Mútua Terrassa, Terrassa, Barcelona, Spain.
Emma PadillaMicrobiology Department. Catlab, Fundació Mútua Terrassa, Terrassa, Barcelona, Spain.
Pepa PérezMicrobiology Department. Catlab, Fundació Mútua Terrassa, Terrassa, Barcelona, Spain.
Marc GarretaMicrobiology Department. Catlab, Fundació Mútua Terrassa, Terrassa, Barcelona, Spain.
Judith VidalMicrobiology Department. Catlab, Fundació Mútua Terrassa, Terrassa, Barcelona, Spain.
Angeles JaenUnitat de Recerca. Fundació, Docència i Recerca Mútua Terrassa, Universitat de Barcelona, Terrassa, Barcelona, Spain.
Helena Monzón CampsInternal Medicine Department, Fundació Mútua Terrassa, Plaça del Doctor Robert, 5, 08221, Terrassa, Barcelona, Spain.
COMUTE Study Group (COVID-19 Mutua Terrassa Study Group)
University Hospital Mútua de Terrassa · ESMútua Terrassa · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we present an 18-month serological follow-up of 294 patients with COVID-19 pneumonia. The aim was to assess the dynamics of serological response and its correlation with clinical worsening, as well as to describe clinical worsening determinants. Results of the study showed an early immunoglobulin M response, which clearly diminished starting at 4 months, but nonetheless, a small group of patients remained positive. As for immunoglobulin G, levels were higher up to 6 months in patients who presented clinical worsening during hospitalization. High titers of the immunoglobulin were maintained in all patients during follow-up, which would indicate that humoral immunity due to infection is long-lasting. Male sex, presence of myalgias and extensive radiological affectation were significantly correlated with clinical worsening.

Indexed as

COVID-19Antibodies, ViralHospitalizationHumansMaleProspective StudiesSARS-CoV-2Antibodies, ViralClinical worseningCOVID-19 pneumoniaSARS-COV-2Serological response

Identifiers

PMID36538188
PMCPMC9765378
OpenAlexW4312211946

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.